Bioinformatics

Carrum Health Taps Pallav Sharda as Chief Platform Officer to Scale Technology Platform

Retrieved on: 
Giovedì, Agosto 12, 2021
Cloud, Vizient, Inc., Sach, Public sector, UnitedHealth Group, Interoperability, Center, Columbia University, COE, HIE, Kaiser Permanente, Health informatics, Bioinformatics, Data science, Entrepreneurship, Industry, Cancer, CEO, Adoption, Multimedia, SAN, Machine learning, Technology, Fortune 500, Omnicell, Partnership, Medical tourism, Academic health science centre, View, Google Cloud, GE Healthcare, Hip, R, Northwestern University, Excellent, Engineering, Memorial Sloan Kettering Cancer Center, Health insurance

SAN FRANCISCO, Aug. 12, 2021 /PRNewswire/ -- Carrum Health , the first digital health company connecting employers and employees to Centers of Excellence (COEs) through a technology-powered platform for higher quality and cost-effective surgical care, today announced it named Pallav Sharda as Chief Platform Officer.

Key Points: 
  • SAN FRANCISCO, Aug. 12, 2021 /PRNewswire/ -- Carrum Health , the first digital health company connecting employers and employees to Centers of Excellence (COEs) through a technology-powered platform for higher quality and cost-effective surgical care, today announced it named Pallav Sharda as Chief Platform Officer.
  • "At Carrum Health, we've built the highest quality network of Centers of Excellence and are leading the much-needed digital transformation of surgical care.
  • Sharda also was the Director of Interoperability and Partnerships at Omnicell and co-founded health IT startup Dovetail Care Inc.
    At Carrum Health, Sharda will oversee engineering, product, data science and design to ensure that the evolving technology platform can effectively scale as the company's member and provider bases grow.
  • I look forward to working with Sach and the entire Carrum Health team to scale this technology to more employers, geographies and service offerings."

OpGen to Provide Business Update and Financial Results for the Second Quarter 2021 on August 12th at 4:30 p.m. Eastern Time

Retrieved on: 
Mercoledì, Agosto 4, 2021
Biotechnology, Molecular diagnostics, Bioinformatics, Lluís Companys, Rockville, Maryland, Life sciences, Biology, Articles

Following the conclusion of the conference call, a replay will be available through August 26, 2021.

Key Points: 
  • Following the conclusion of the conference call, a replay will be available through August 26, 2021.
  • The live, listen-only webcast of the conference call may also be accessed by visiting the Investors section of the Companys website at www.opgen.com .
  • A replay of the webcast will be available following the conclusion of the call and will be archived on the Companys website under Financials & Filings.
  • OpGen, Inc. (Rockville, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease.

Pacific Biosciences Acquires Circulomics – A Leading High Molecular Weight DNA Extraction Company

Retrieved on: 
Martedì, Agosto 3, 2021
Branches of biology, Biology, Life sciences, DNA sequencing, Molecular biology, Biotechnology, Pacific Biosciences, DNA, Bioinformatics, Third-generation sequencing, Read, DNA sequencer

MENLO PARK, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB) (Pacific Biosciences or PacBio), a leading provider of high-quality, long-read sequencing platforms, announced today that it acquired Circulomics Inc. (Circulomics), a Maryland-based biotechnology company focused on delivering highly differentiated sample prep products that enable genomic workflows.

Key Points: 
  • MENLO PARK, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB) (Pacific Biosciences or PacBio), a leading provider of high-quality, long-read sequencing platforms, announced today that it acquired Circulomics Inc. (Circulomics), a Maryland-based biotechnology company focused on delivering highly differentiated sample prep products that enable genomic workflows.
  • Scientists recognize Circulomics as a leader in extracting high quality, high molecular weight (HMW) DNA from almost any sample type.
  • High quality, long-read sequencing begins with high quality, long DNA.
  • Circulomics Nanobind magnetic disks protect DNA from shearing to generate long reads across a broad range of sample types.

Personal Genome Diagnostics Appoints Jamie Platt, Ph.D., as Chief Operations Officer

Retrieved on: 
Martedì, Agosto 3, 2021
Biotechnology, Genetics, Health, Clinical trials, Branches of biology, Biology, Genetics, Genomics, Biotechnology, Bioinformatics, DNA, Whole genome sequencing

Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today announced the appointment of Jamie Platt, Ph.D., as Chief Operations Officer.

Key Points: 
  • Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today announced the appointment of Jamie Platt, Ph.D., as Chief Operations Officer.
  • The addition of a Chief Operations Officer to the PGDx management team is an invaluable one as we continue to grow our product roadmap and services offerings, driven by relentless commitment to improving cancer care on a global scale, said Megan Bailey, Chief Executive Officer.
  • Personal Genome Diagnostics (PGDx) empowers the fight against cancer by unlocking actionable information from the genome.
  • PGDx was established by researchers from Johns Hopkins University who are pioneers in cancer genome sequencing and liquid biopsy technologies.

Global Biochips Market Report to 2024 - Trends, Forecast, and Competitive Analysis - ResearchAndMarkets.com

Retrieved on: 
Giovedì, Luglio 29, 2021
Medical devices, Health, Branches of biology, Biology, Life sciences, Microarrays, Molecular biology, Biotechnology, Bioinformatics, Biochip, Genomics

The study includes the biochip market size and forecast for the global biochip market through 2024, segmented by chip type, fabrication technology, application, material, end use, and region.

Key Points: 
  • The study includes the biochip market size and forecast for the global biochip market through 2024, segmented by chip type, fabrication technology, application, material, end use, and region.
  • Some of the features of 'Global Biochip market 2019-2024: Trends, Forecast, and Opportunity Analysis' include
    Market size estimates: Global biochips market size estimation in terms of value ($M) shipment.
  • Growth opportunities: Analysis on growth opportunities in different applications and regions for biochips in the global biochip market.
  • Strategic analysis: This includes M&A, new product development, and competitive landscape for, biochips in the global biochip market.

Dr. Thomas Halsey Joins Discovery Life Sciences As Executive Vice President

Retrieved on: 
Giovedì, Luglio 29, 2021
Bioinformatics

"We are thrilled to welcome Tom to Discovery during this exciting time in our company's growth," saidDr.

Key Points: 
  • "We are thrilled to welcome Tom to Discovery during this exciting time in our company's growth," saidDr.
  • Dr. Halsey comes to Discovery following nearly a decade of service at Q2Solutions, where he most recently served as senior director and global head of genomic laboratory operations.
  • HudsonAlpha Discovery is Discovery's sequencing and bioinformatics division, a globally recognized service laboratory that leverages the most current genomic research technologies to comprehensively support discovery, translational, and clinical research.
  • Driven by science, the Discovery team engages with customers in an innovative, consultative approach to overcoming obstacles and reaching a fasterend result.

Schrödinger Hosts First Annual Educator’s Day and Announces “Teaching with Schrödinger” Program

Retrieved on: 
Mercoledì, Luglio 28, 2021
Software, Biotechnology, Pharmaceutical, Health, Technology, University, Education, Clinical trials, Bioinformatics

Also today, the company announced Teaching with Schrdinger, a new initiative to develop curricula for academic institutions to teach students about chemical interactions, drug design and materials research using Schrdinger software.

Key Points: 
  • Also today, the company announced Teaching with Schrdinger, a new initiative to develop curricula for academic institutions to teach students about chemical interactions, drug design and materials research using Schrdinger software.
  • Educators Day will feature presentations from skilled instructors who have successfully incorporated computational tools into courses ranging from organic chemistry to bioinformatics to pharmaceutical science.
  • In addition, Schrdinger scientists will host breakout sessions to brainstorm new approaches for engaging students with the material and drawing connections to real-world applications.
  • Founded in 1990, Schrdinger has over 450 employees and is engaged with customers and collaborators in more than 70 countries.

eureKARE launches inaugural eureKAWARDS to support European synthetic biology innovation

Retrieved on: 
Mercoledì, Luglio 28, 2021
Articles, Life sciences, Biology, Bioinformatics, Biotechnology, Appropriate technology, Biocybernetics, Synthetic biology, Synbio, Synthetic

The winner will receive free access to eureKAREs synthetic biology studio, eureKASYNBIO, for one year.

Key Points: 
  • The winner will receive free access to eureKAREs synthetic biology studio, eureKASYNBIO, for one year.
  • The winner will also receive guidance and support from eureKAREs team and broad network of validated academic and industrial professionals in synthetic biology.
  • Rodolphe Besserve, Chief Executive Officer of eureKARE, echoed: The first eureKAWARDS is an exceptional opportunity for researchers across Europe to showcase their ideas as part of an event looking to celebrate and support synthetic biology.
  • eureKARE is a unique project development company dedicated to investing and developing next generation biotechnology companies in the cutting-edge fields of the microbiome and synthetic biology.

Global Medical Imaging & Informatics Market Thrives with AI and Cloud as Healthcare Sector Focuses on Quadruple Aim

Retrieved on: 
Lunedì, Luglio 26, 2021
Academic disciplines, Bioinformatics, Imaging informatics, Medical imaging, Articles, Informatics

SANTA CLARA, Calif., July 26, 2021 /PRNewswire/ -- The healthcare sector's emphasis on meeting its Quadruple Aim goal—cost reduction, clinical outcomes, enhance the patient and caregiver experience, and improve the work-life of healthcare providers—encourages the medical imaging and informatics industry to use advanced technologies to tap into growth prospects. Frost & Sullivan's recent analysis, Global Medical Imaging & Informatics Outlook, 2021, finds that the market opportunity is estimated to hit $37.10 billion in 2021 from $33.90 billion in 2020, registering growth at 9.4% under an aspirational scenario.

Key Points: 
  • Frost & Sullivan's recent analysis, Global Medical Imaging & Informatics Outlook, 2021, finds that the market opportunity is estimated to hit $37.10 billion in 2021 from $33.90 billion in 2020, registering growth at 9.4% under an aspirational scenario.
  • For further information on this analysis, please visit: http://frost.ly/62v
    "As the medical imaging and informatics industry evolves rapidly, there are opportunities for vendors to grow by inorganic routes and widen their portfolio of artificial intelligence (AI) offerings.
  • With advancements in AI and the cloud, the medical imaging and informatics industry experiences rapid transformation, creating growth opportunities for its market participants, including:
    Emphasis on cloud-based imaging informatics: Vendors can sign business associate agreements with cloud service providers to assume responsibility in the event of data breaches.
  • Global Medical Imaging & Informatics Outlook, 2021

Global Medical Imaging & Informatics Market Thrives with AI and Cloud as Healthcare Sector Focuses on Quadruple Aim

Retrieved on: 
Lunedì, Luglio 26, 2021
Academic disciplines, Bioinformatics, Imaging informatics, Medical imaging, Articles, Informatics

SANTA CLARA, Calif., July 26, 2021 /PRNewswire/ -- The healthcare sector's emphasis on meeting its Quadruple Aim goal—cost reduction, clinical outcomes, enhance the patient and caregiver experience, and improve the work-life of healthcare providers—encourages the medical imaging and informatics industry to use advanced technologies to tap into growth prospects. Frost & Sullivan's recent analysis, Global Medical Imaging & Informatics Outlook, 2021, finds that the market opportunity is estimated to hit $37.10 billion in 2021 from $33.90 billion in 2020, registering growth at 9.4% under an aspirational scenario.

Key Points: 
  • Frost & Sullivan's recent analysis, Global Medical Imaging & Informatics Outlook, 2021, finds that the market opportunity is estimated to hit $37.10 billion in 2021 from $33.90 billion in 2020, registering growth at 9.4% under an aspirational scenario.
  • For further information on this analysis, please visit: http://frost.ly/62v
    "As the medical imaging and informatics industry evolves rapidly, there are opportunities for vendors to grow by inorganic routes and widen their portfolio of artificial intelligence (AI) offerings.
  • With advancements in AI and the cloud, the medical imaging and informatics industry experiences rapid transformation, creating growth opportunities for its market participants, including:
    Emphasis on cloud-based imaging informatics: Vendors can sign business associate agreements with cloud service providers to assume responsibility in the event of data breaches.
  • Global Medical Imaging & Informatics Outlook, 2021